{"doc_id": "32941801", "type of study": "Therapy", "title": "", "abstract": "Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly.\nBCG vaccination in children protects against heterologous infections and improves survival independently of tuberculosis prevention.\nThe phase III ACTIVATE trial assessed whether BCG has similar effects in the elderly.\nIn this double-blind, randomized trial, elderly patients (n\u00a0= 198) received BCG or placebo vaccine at hospital discharge and were followed for 12\u00a0months for new infections.\nAt interim analysis, BCG vaccination significantly increased the time to first infection (median 16\u00a0weeks compared to 11\u00a0weeks after placebo).\nThe incidence of new infections was 42.3% (95% CIs 31.9%-53.4%) after placebo vaccination and 25.0% (95% CIs 16.4%-36.1%) after BCG vaccination; most of the protection was against respiratory tract infections of probable viral origin (hazard ratio 0.21, p\u00a0= 0.013).\nNo difference in the frequency of adverse effects was found.\nData show that BCG vaccination is safe and can protect the elderly against infections.\nLarger studies are needed to assess protection against respiratory infections, including COVID-19 (ClinicalTrials.gov NCT03296423).\nCopyright \u00a9 2020 Elsevier Inc. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "children", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 27}, {"term": "elderly", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 84}, {"term": "elderly patients", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 58}, {"term": "elderly", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 66}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Activate : Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "BCG Vaccination", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 55}], "Outcome": [{"term": "Infection", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 73}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "BCG vaccination in children protects against heterologous infections and improves survival independently of tuberculosis prevention .", "Evidence Elements": {"Participant": [{"term": "children", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 27}], "Intervention": [{"term": "BCG vaccination", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 15}], "Outcome": [{"term": "heterologous infections", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 68}, {"term": "survival", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 90}, {"term": "tuberculosis prevention", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 131}], "Observation": [{"term": "protects", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 36}, {"term": "improves", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 81}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The phase III ACTIVATE trial assessed whether BCG has similar effects in the elderly .", "Evidence Elements": {"Participant": [{"term": "elderly", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 84}], "Intervention": [{"term": "BCG", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 49}], "Outcome": [{"term": "effects", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 69}], "Observation": [{"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 61}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In this double-blind , randomized trial , elderly patients ( n = 198 ) received BCG or placebo vaccine at hospital discharge and were followed for 12 months for new infections .", "Evidence Elements": {"Participant": [{"term": "elderly patients", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 58}], "Intervention": [{"term": "BCG", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 83}, {"term": "placebo vaccine", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 102}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "At interim analysis , BCG vaccination significantly increased the time to first infection ( median 16 weeks compared to 11 weeks after placebo ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "BCG vaccination", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 37}], "Outcome": [{"term": "time to first infection", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 89}], "Observation": [{"term": "significantly increased", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 61}, {"term": "16 weeks", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 107}, {"term": "11 weeks", "negation": "affirmed", "UMLS": {}, "start": 120, "end": 128}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The incidence of new infections was 42.3 % ( 95 % CIs 31.9 % -53.4 % ) after placebo vaccination and 25.0 % ( 95 % CIs 16.4 % -36.1 % ) after BCG vaccination ; most of the protection was against respiratory tract infections of probable viral origin ( hazard ratio 0.21 , p = 0.013 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo vaccination", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 96}, {"term": "BCG vaccination", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 157}], "Outcome": [{"term": "incidence of new infections", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 31}], "Observation": [{"term": "42.3 %", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 42}, {"term": "25.0 %", "negation": "affirmed", "UMLS": {}, "start": 101, "end": 107}], "Count": []}, "Evidence Propositions": [{"Intervention": "placebo vaccination", "Observation": "42.3 %", "Outcome": "incidence of new infections", "Count": ""}, {"Intervention": "BCG vaccination", "Observation": "25.0 %", "Outcome": "incidence of new infections", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "No difference in the frequency of adverse effects was found .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "frequency of adverse effects", "negation": "negated", "UMLS": {}, "start": 21, "end": 49}], "Observation": [{"term": "difference", "negation": "negated", "UMLS": {}, "start": 3, "end": 13}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "difference", "Outcome": "frequency of adverse effects", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Data show that BCG vaccination is safe and can protect the elderly against infections .", "Evidence Elements": {"Participant": [{"term": "elderly", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 66}], "Intervention": [{"term": "BCG vaccination", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 30}], "Outcome": [{"term": "infections", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 85}], "Observation": [{"term": "safe", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 38}, {"term": "protect", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 54}], "Count": []}, "Evidence Propositions": [{"Intervention": "BCG vaccination", "Observation": "protect", "Outcome": "infections", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Larger studies are needed to assess protection against respiratory infections , including COVID-19 ( ClinicalTrials.gov NCT03296423 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Inc . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}